The current animal-based paradigm for safety assessment must change. In September 2016, the UK National Centre for Replacement, Refinement and Reduction of Animals in Research (NC3Rs) brought together scientists from regulatory authorities, academia and industry to review progress in bringing new methodology into regulatory use, and to identify ways to expedite progress. Progress has been slow. Science is advancing to make this possible but changes are necessary. The new paradigm should allow new methodology to be adopted once it is developed rather than being based on a fixed set of studies. Regulatory authorities can help by developing Performance-Based Standards. The most pressing need is in repeat dose toxicology, although setting standards will be more complex than in areas such as sensitization. Performance standards should be aimed directly at human safety, not at reproducing the results of animal studies. Regulatory authorities can also aid progress towards the acceptance of nonanimal based methodology by promoting "safe-haven" trials where traditional and new methodology data can be submitted in parallel to build up experience in the new methods. Industry can play its part in the acceptance of new methodology, by contributing to the setting of performance standards and by actively contributing to "safe-haven" trials.
Introduction
In the 50 years since Russell and Burch (1959) first introduced the concept of the 3Rs -the reduction, refinement, and replacement of the use of animals in research -there have been increasing requirements for scientists using animals in their daily work to consider and incorporate these guiding principles into their research. However, one area that remains heavily reliant on animal models is safety assessment, in which toxicity tests are carried out to ascertain whether manufactured products pose a threat to the health of humans or the environment. Burden et al. (2015a) noted that recent years have seen a turning point in our ability to consider the risk of chemicals to humans and the environment by using more data from non-animal technologies. There is great potential to apply these scientific and technological advances to reduce reliance on animal tests and to establish testing paradigms that bear more human and real-life relevance. Numerous collaborative research initiatives underway hold real promise to provide the scientific foundations that are required to increase confidence in non-animal methods. Burden et al. (2015a) called for the industry and regulatory communities to work together to ensure that these achievements are applied in practice, so that safety assessment strategies can both be improved and animal use can be reduced. In order to facilitate such collaboration, the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) ran a session at their Toxicology Showcase Event in London, UK in September 2016 which brought together 70 expert scientists from regulatory authorities, academia and industry (pharmaceutical, agrochemicals, industrial chemicals and consumer products) to review the rate of progress in bringing new methodology into regulatory use in a globally harmonised way, and to identify ways to expedite progress in the next coming years. This paper incorporates aspects of the discussion which took place.
The practice of toxicology needs to change
There is a growing realisation that the practice of toxicology will change markedly from the present well-established laboratory animal study-based paradigm. The current system is very resource intensive, requiring large numbers of laboratory animals and manhours, it takes a long time to assess the safety of one chemical or pharmaceutical fully (3e4 years) and it is very expensive. In addition, there is a view that the current testing practices pose inherent problems in extrapolating the results of studies conducted at often high doses in laboratory animals to the typically lower doses experienced by humans and other environmental species.
Continuing advances in biological science and technology coupled with advances in data availability and manipulation have fostered the view that a new way of performing toxicology could be developed (NRC, 2007) . The now seminal National Research Council (NRC) report envisages the use of in silico, in vitro and nonregulatory in vivo techniques individually or together in integrated strategies to assess the toxicology of chemicals. It is foreseen that ultimately the use of laboratory animals for toxicity testing will be replaced by non-animal techniques, although reaching that goal was recognised to be some time away when the report was published in 2007.
Ten years later, the National Academy of Sciences (2017) has reviewed the progress made since then and concluded that the non-traditional data that are being generated today can be effectively used to assess the risks posed by chemicals to humans. However, they emphasise that communicating the strengths and limitations of the approaches in a transparent and understandable way will be necessary if the results are to be applied appropriately and that this will be critical for the ultimate utility and acceptance of the alternative/new non-animal approaches. This is an important step which was rarely considered in the development of the classical animal-based studies which were designed empirically.
What is changing and what is driving the change?
The new toxicology paradigm is being driven by the idea that molecular and cellular changes are the initiating events for the downstream adverse effects captured as apical endpoints in regulatory studies. If these initiating events can be identified, and then the downstream effects predicted using mechanistically-based assays, there will be no need to go on to elucidate them in whole animal studies. Techniques such a genomics, metabolomics and a battery of high throughput assays are being developed in pursuit of this goal. The concepts of Adverse Outcome Pathways (AOPs) and Mode of Action (MoA) have arisen from this idea. Furthermore, methods to predict metabolism and kinetics from physicochemical properties and in vitro assays are being used to aid in the extrapolation of results generated in vitro to in vivo exposures e the socalled (quantitative) in vitro to in vivo extrapolation ((Q)IVIVE). This approach allows the results of in vitro assays to be used to predict in vivo dose response relationships, which is essential for full hazard characterisation and risk assessment. In addition to these developments, advances in computing are allowing the body of knowledge generated in the last 40 years to be curated into databases to serve as the reference data for the development of predictive methods and their evaluation. As part of the curation process, the relevance to humans should be established as far as possible by reference to human data. These three components, mechanistic information, translation of findings to the in vivo situation, and existing data, can be brought together into Integrated Approaches for Testing and Assessment (IATA) or Defined Approaches (DAs) where two or more non-animal methods are combined to provide a sufficient level of information to make regulatory safety decisions about chemicals (OECD, 2016a; OECD, 2017) .
The political drivers to develop the new toxicology come mainly from two directions e the desire to reduce animal numbers used in safety assessment, and the need for higher throughput approaches to enable the evaluation of the significant gaps in toxicological data for chemicals already on the market. There is a concern that less than 5% of the large number of chemicals currently in commercial use (approximately 50,000) have been fully tested (Fischetti, 2010 There is also now provision in Annexes VII and VIII of the REACH legislation for the use of 'validated' alternative methods, including non-testing approaches such as read-across, though methods still have to be suitable to fulfil classification requirements (EU, 2006) . The pressure to reduce animal testing in Europe led to a ban on the testing and marketing of personal care products and ingredients tested on animals in March 2013 (EU, 2009), and household products in the UK in October 2015 (UK Government, 2015), although few alternative methods or IATAs/DAs to assess their safety have been formally approved.
What is the current rate of progress?
Skin corrosivity is arguably one of the simplest adverse effects to model in vitro, and it took almost 20 years for a test guideline addressing this endpoint to be adopted at the Organisation for Economic Co-operation and Development (OECD) and nearly 30 years for an integrated assessment approach. Papers describing in vitro methods for the assessment of skin corrosivity started to appear in the mid-1980s (Oliver et al., 1986 ) and the first interlaboratory trial was reported in 1992 (Botham et al., 1992) . A ring trial sponsored by EURL-ECVAM started in 1998 (Barratt et al., 1998) . The method was finally considered sufficiently valid to be adopted as an official OECD test guideline in 2004 (OECD, 2004 , and was included in an OECD guidance document on an IATA for assessing skin corrosivity and irritation in 2014 (OECD, 2014). There are still ongoing activities and resource dedicated to this area (i.e. method development for skin/eye irritation), which could perhaps be better applied to make progress in other areas.
Further evidence of the relatively slow rate of progress is shown in Table 1 , which demonstrates the range of assessments required for the safety evaluation of a chemical according to the categories suggested by Basketter et al. (2012) . The currently accepted OECD non-animal test guidelines are shown under each heading. It is noteworthy that, although work on refinement and replacement is underway, the columns for acute systemic toxicity, repeat dose toxicity, carcinogenicity, and developmental and reproductive toxicity -some of the lengthiest and most severe tests currently conducted in animals -are blank, except for assays aimed at identifying some of the mechanisms which could be used as part of the body of evidence which lead to the identification of a potential endocrine disruptor according to the WHO definition (OECD, 2012) .
OECD Mutual Acceptance of Data states that "test data generated in any member country in accordance with OECD Test Guidelines and Principles of Good Laboratory Practice (GLP) shall be accepted in other member countries for assessment purposes and other uses relating to the protection of human health and the environment". However, national and regional regulatory authorities are not obliged to use them in their own mandated testing packages. The test guidelines represent a list of potential tests which can be used, but each authority is free to include them in their requirements or not. Clearly this current rate of progress is not going to allow a move away from animal-based studies within the 21st century, or support the testing needs for chemicals under REACH and TSCA, and something needs to change. The need for change also applies to the pharmaceutical, veterinary medicine, plant protection, biocide and personal care sectors.
What must change to allow the regulatory use of nonanimal data?
The routine use of non-animal approaches within a safety assessment context will only be achieved if there is a) widespread acceptance of the data by regulatory bodies, and b) relevant changes in policy, guidance and legislation. There are a number of issues that still remain to be addressed, including increasing confidence within companies to submit non-traditional data to regulators, and ensuring that regulators have sufficient confidence in assessing and interpreting data from non-traditional sources, as well as the legislative framework to support their ability to accept such data, for example in the 2016 amendments to Annexes VII and VIII of the REACH legislation (EU, 2006) .
One of the key hurdles to enabling widespread regulatory acceptance is proving that an alternative method or approach is robust, reproducible, relevant and fit for the purpose intended. Processes have been established to standardise test method validation, for example those provided by bodies such as EURL-ECVAM. These scientifically rigorous processes are associated with significant financial and time investment. Considering the vast number of in vitro assays and increasingly mechanistically-based in silico models of biological pathways/networks which have potential to be applied in chemical toxicity screening or assessment, there is a clear need for a more streamlined approach to demonstrate the robustness and utility of these approaches. This also extends to agreement on how best to apply weight of evidence where integrated testing strategies are used, and how to select appropriate approaches (and the combinations thereof) once toolboxes of robust methods are established, depending on the safety assessment questions to be answered. The validation process would also benefit from a culture shift away from benchmarking results against the current animal models which themselves are not perfect in terms of their predictions for humans and instead where possible concentrate on addressing the high specificity and sensitivity of human-relevant tests that is expected by regulators (Burden et al., 2015b) .
As most companies aim to market their products internationally, there is also a need for the requirements of different global regions to become more streamlined to ensure that redundant in vivo tests are not carried out to satisfy requirements in a minority of regions. There is scope in the short term to identify good practice within the current requirements to enable immediate reductions in the numbers of animals used for global registrations, and in the long-term to identify opportunities for better harmonisation and increased mutual data acceptance across regions. There are mutual acceptance agreements within OECD member countries, but this must be enforced to have any benefit. As mentioned, OECD countries can still choose to have and follow local (non-OECD) test guidelines.
The aim of the discussions at the NC3Rs workshop was to explore the barriers/challenges to the regulatory acceptance of data from non-animal approaches. Three questions were considered:
Question 1: What should a non-animal data package look like (e.g. involving performance based acceptance of multiple assays and methods to integrate them)?
The discussions revealed a shared vision of what the future should look like, and how it would differ from the current approach. There should not be an attempt to create one in vitro or in silico test to replace each animal model. Non-animal models will be used in combination: animals integrate the range of systems and processes which need to be considered in safety assessment, and reproducing the range and integration is scientifically difficult.
The questions to be addressed by safety evaluation need to be refined. At the moment, the questions are primarily hazard-driven and can be summarised as: And one that should be considered but is often lacking under some regulatory frameworks:
▪ Are humans or environmental species likely to be exposed to these doses?
If a non-animal test fails to reproduce the answer to the first question in its entirety then the test would be deemed unsatisfactory.
These questions need to be reformulated in order for progress to be made, and in a tiered approach to firstly address the exposure scenario:
▪ What doses of the chemical are humans likely to be subjected to? ▪ How likely are adverse effects at these doses?
This would allow the safety assessment to be targeted at the exposure conditions and to the chemical of interest. It would allow exposure-based waiving and would inform dose setting for assays, so that a testing strategy could be developed taking the specific chemical into account. If the likely human exposure is low, then the methodology which is used to assess the potential toxicity need not be as precise as when doses are higher, nor may the hazard need to be considered at all since significant exposure is unlikely. Assessing effects when human exposure is low can tolerat a greater margin for conservatism in the methodology, for instance application of the Threshold of Toxicological Concern (TTC). This approach requires that a no observed adverse effect level (NOAEL) is determined for a large number of chemicals within an area of chemistry. A conservative assumption is then made that any untested chemicals in that class are as potent as the most potent 5% of chemicals in that class, and assigns them a presumed very low NOAEL accordingly, although the possible range of potencies spans several orders of magnitude. If the exposure falls below the TTC, the likelihood of adverse effects is predicted to be low, and in these cases the TTC approach though imprecise, may allow a risk assessment decision to be made.
The RISK21 (Risk assessment in the 21st Century) framework has been developed based on this concept e enough precision to make the decision Embry et al., 2014) . This RISK21 process emphasises the need to start with problem formulation based on the frequency and duration of human exposure. This can limit the extent of the assessment which is required. When exposures are likely to be higher, greater degrees of precision are required, but the range of potential adverse effects which may be of concern could be narrowed by a stepwise, tailored approach. The time has come to remove requirements to assess irrelevant toxicity, for example, high dose toxicity which has limited relevance for exposure resulting from lower doses. It will be important to define and focus on the scientific question on a case-by-case basis, and incorporate exposure and intended use considerations into the safety assessment process accordingly.
Following consideration of exposure, the initial steps in identifying hazard potential would be based on comparison with other chemicals using in silico approaches and a range of in vitro assays which would be used to identify pathways of toxicity which are or are not triggered, and prioritise/identify those which require more detailed evaluation. The range of studies would be specific to the chemical and its use and not form part of a mandated package. The use of the AOP concept allows identification of assays to define key events within a biological pathway which can be put together in combination within IATA frameworks to predict whole animal outcome, rather than specific key events. 'Building blocks' of approaches may be the answer, so that a combination of assays/approaches can be built and applied to answer the relevant scientific questions. This is in contrast to the current regulatory requirements in the pharmaceutical, agrochemical/biocide, veterinary and general chemical sectors that mandate which studies should be performed, with a limited degree of flexibility based on the use of the test substance. These methods have been developed and international guidelines agreed over a period of nearly 40 years. This has in In the future methodology will continue to develop at such a pace that it is unlikely such rigidity of test requirements will be possible. Methods may be replaced or used in combination with other tests in an IATA. The results of an individual test may have a different influence on the outcome of an assessment if tools such as Bayesian networks are used to combine the results of different suites of assays. Bayesian networks provide a mathematical tool for dealing with uncertainty and complexity and they are playing an increasingly important role in the design and analysis of machine learning algorithms. For example, Jaworska et al. (2015) have developed a Bayesian network which combines in vitro and in silico assay data assessing different aspects of skin sensitization into an integrated testing strategy with the aim of estimating sensitizing potency in the local lymph node assay (LLNA).
A different approach to the regulatory acceptance of methodology will be required. It is likely to be performance-based (i.e. following Performance Based Test Guidelines e PBTGs) rather than protocol-based. This means that the development and validation of test methods is done with reference to a set of performance standards. This will allow new test methods to be used as they are developed, once they have been reviewed and agreed as meeting the standard. At the moment, PBTGs are used assay by assay, for instance the OECD has issued a PBTG for the use of stably transfected transactivation assays for oestrogen receptor agonists and antagonists (OECD, 2016b) . Rather than endorsing one method, the guideline provides a list of performance standards and acceptable range values that a new similar modified method must meet. If this can be demonstrated the method can be used, thus allowing for new methods to be developed. This principle could be extended to IATAs which integrate a range of methods. The individual studies could be changed as methodology improves provided the overall IATA meets the required performance standard. This is relatively simple to do for an endpoint such as skin sensitization, indeed the IATA developed by Jaworska et al. (2015) could be considered to be an example of how this can be achieved. However, it will need some careful thought to apply the same principle to more complex outcomes such as repeat dose toxicity. The performance standards need to be chosen with the outcome in mind. For instance, in some situations it might be precise enough to be able to determine the overall NOAEL to within one order of magnitude without specifying the exact toxicity which would set the NOAEL. In other situations, much more precision might be required to estimate the NOAEL and the toxic effect which could occur. It should be borne in mind that the current methodology often builds in an uncertainty factor of two orders of magnitude to account for interspecies and intraspecies variability.
Question 2: How can data package requirements be designed to meet cross-sector needs (i.e., suitable for all chemical types) and be suitable for international registrations, to ensure streamlined processes that are applicable to all chemical types globally?
Firstly, it is important to be clear about the scientific question to be answered e there are different needs across sectors, therefore a cross-sector approach may not always be possible and approaches may be needed that are more tailored to each segment. However, common principles are likely to emerge and shared concepts will be used to put together approaches which are shaped by both the human dose/exposure, and the properties of the chemical being assessed.
Although each sector will develop its own framework for safety assessment, the sectors can learn from each other, and they should share and collaborate more to encourage best practice. A good example of how this can be done is the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). It brings together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH's mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. There is a veterinary medicine equivalent International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) which aims to harmonise technical requirements for data necessary for the marketing authorisation of a veterinary medicinal product. This is achieved by developing harmonised guidelines on the studies to be submitted in a marketing authorisation application. There is a need for equivalent bodies that cover other sectors.
The OECD is starting to take this role on for agrochemicals/ biocides and general chemicals in the development of guidance documents on safety assessment, rather than limiting itself to the adoption of individual assays and studies. The OECD Conceptual Framework for testing and assessment of endocrine disruptors (OECD, 2012) is a good example. The framework assigns currently available studies and assays into five levels and gives guidance on how the information from studies can be used in combination to assess endocrine activity. New assays can be placed into the framework as they are developed so it avoids ossification while allowing continuity. The OECD (2016b) has also provided guidance on the development of IATAs which does not specify methods but provides guidance on how to put them together, and on the reporting of DAs within an IATA (OECD, 2017).
Question 3: Is it feasible for an internationally agreed testing and validation framework to be established for non-animal methods?
As demonstrated in section 3, the current ECVAM and other validation processes are very slow and long-winded. Tests will become outdated before they are validated if this methodology is continued. Performance standards are needed to facilitate the timely acceptance of new methodologies. In future, the setting of performance standards will become the major role of the organisations which set regulatory requirements such as US EPA, US FDA, ECHA and EFSA. Developing a philosophy and guidance for setting performance standards for safety assessment methodology should be a major activity for regulatory authorities in the next few years. These will need to draw on the collected knowledge which has been gained from the last 40e50 years of safety assessment which has been codified into databases such as RepDose Data Base (Fraunhofer, 2017) and ToxRefDB (EPA, 2017b) .
At the moment, data from OECD studies are in theory mutually acceptable, but the overall safety assessment is carried out in regions or countries which may have a preference for particular test guidelines or species. In the future, there needs to be more consistency in how safety assessments are made across the globe e moving from MAD (mutual acceptance of data) to MAA (mutual acceptance of assessment). Organisations such as ICH and OECD will be invaluable for achieving this.
The move to non-animal based safety assessment will be different in each regulatory sector (pharmaceuticals, agrochemicals/biocides, veterinary products, general chemicals, and personal care). However, it is possible to envisage a similar transitional process in each sector, although the time scale for each phase would be different (Fig. 1) . The phases could be characterised by what will be mandated for regulatory decision making:
Phase 1. Animal Studies e definitive safety assessments require the results of animal studies. Non-animal studies are used for screening and explanation. Phase 2. Animal Studies with Non-Animal-based Study Waiving e definitive safety assessments made using animal studies, but some studies will not be required if non-animal data indicate they are not needed. Phase 3. Non-Animal studies with Animal Studies in Exceptional Circumstances e definitive safety assessments will be made using non-animal data but some animal studies will be necessary to address uncertainty. Phase 4. Non-Animal Studies e definitive safety assessments will be made using non-animal data and no animal data will be required/allowed.
The Agrochemicals/Biocides Sector is the least advanced being in phase 1. There is pressure to move to phase 2, but progress is slow. The movement to phase 2 is likely to start with challenges to requests for supplementary studies from registrants, the removal of redundant requirements, for instance the one year dog study is no longer required in most regions (Dellarco et al. 2010) , and then move towards replacing some core studies over the next 10 years. There is considerable political resistance to anything which can be interpreted as relaxing standards on pesticide safety, and study waiving could be potentially perceived in this way by environmental activist groups who declare an inherent distrust of agrochemicals. However, animal welfare pressure will push to move Agrochemicals/Biocides into phase 3 following the progression of the General Chemicals Sector who are currently further along this progression scale (see below). The view will be taken that if safety assessment can be assured without the use of animals for general chemicals, then similar ethical considerations should be applied to agrochemicals/biocides.
The Pharmaceuticals Sector is entering phase 2. The ICH initiative on cancer testing (ICH, 2016) is an example of this in action. Over the next five years, data will be collected from shorterterm animal studies which may lead to the number of compounds requiring long-term (18 month/two year) bioassays to be drastically reduced. There will be an increasing demand for predictive and explanatory studies from this sector. However, the pharmaceuticals sector is likely to be the last sector to get to phase 3, as concerns over drug safety will remain high. It will be more difficult to use a safe margin of exposure approach for pharmaceuticals, which may ultimately be more effective in Agrochemicals/Biocides, because the therapeutic window, i.e. the gaps between the doses required to achieve desired therapeutic effects and unwanted adverse effects, are relatively small. The direct personal benefits of pharmaceuticals may limit the public pressure to stop using animals based on ethical concerns, and ultimately this sector may never get to phase 4. Pharmaceuticals are dosed at biologically-active doses and there will be concerns over safety based on the anxiety caused by high profile cases where clinical trials have shown adverse effects, despite being shown to be 'safe; in animal studies (Goodyear, 2006) . The General Chemicals Sector is currently in phase 2. There are definitive animal study requirements, but waiving is allowed based on very low exposure scenarios and/or read across. There is considerable scientific effort and public/political push for a move to phase 3. This could take another 10 years, but the proportion of toxicology using non-animal studies will grow during this period.
The Personal Care Sector is in phase 4 in the EU. It was pushed there by legislation (EU, 2009) directly from Phase 1, without going through the other phases, and without the tools to function at this Phase. Aside from skin sensitization, the regulatory authorities have approved very few non-animal methods, and even in this case how to use this data in safety assessment is lacking. This will in the medium-term cause problems for innovations involving new materials/ingredients, as there are not yet the means to carry out nonanimal risk assessments for new ingredients. However the major personal care companies are investing in new methodologies which may in turn be of advantage to other sectors.
A "guesstimate" of the likely timescale for progress through the phases is shown in Fig. 1 .
Progress through the phases could be expedited using a "safe haven" approach for trials of new approaches. The ICH trial for new approaches to carcinogenicity assessment is an example of this (EMA, 2016) . The results of new methodology were submitted alongside assessments using traditional methods and at the end of the trial period the results will be compared. However, no regulatory decisions will be taken based on the new methodology, the results will be used only for the purposes of the trial. This principle could be extended into agrochemicals/biocides, veterinary products and to general chemicals. The Joint Food and Agriculture Organisation (FAO) and World Health Organisation (WHO) Meeting on Pesticide residues (JMPR), which evaluates pesticide residues, has called for the submission of data based on new methodology. JMPR would be ideally placed to host such a trial of new methodology for agrochemicals. The European Chemicals Agency (2016) (ECHA), responsible for enforcement of the REACH regulation, is encouraging the use of what they term "New Approach Methodology" and have sponsored trials of the use of alternative methods to improve confidence in read-across.
Conclusion
There has been a growing realisation that the current laboratory animal-based paradigm for safety assessment must change. Rotroff et al. (2010) state that "The current paradigm for testing agricultural and industrial chemicals for potential human health effects is Fig. 1 . Projection of rate of progress through phases towards non-animal based safety assessment for the different industry sectors. inefficient, expensive, and relies heavily on experimental animals." Andersen and Krewski (2009) point out that the drive to use new methodology should be driven by improvements to toxicity testing, rather than alternatives to animals. There is however no doubt that these aspects go hand-in-hand. Progress has been slow, but recent developments indicate that this is on the verge of change. The science is advancing to make this possible. Changes will be necessary in the way new methodology is evaluated to prove it is fit for purpose as part of an IATA. For instance, using "safe haven" trials, and changes in the way regulations are framed, to be flexible and standards/performance-based rather than protocol and studybased, will ensure the new methodology is accepted.
Regulatory authorities can bring forward the day when they can increase their acceptance of non-animal methods in two ways. Firstly, by working to develop internationally agreed performancebased standards for new methodologies. The most pressing need is in repeat dose toxicology, including carcinogenicity and reproductive toxicity. Setting of standards will be more complex than in more focused areas such as sensitization and irritation, but nevertheless it is unlikely that non-animal methods will ever be accepted without defining performance standards. In addition, the new systems should allow for new methodology to be used as and when it is developed without having to redefine the whole process of safety assessment. There will be debate as to whether the performance standards should be set on the basis of trying to reproduce the results of animal studies or be aimed directly at human and/or environmental safety. The second way regulatory authorities can aid progress towards the acceptance of non-animal based methodology is to promote "safe haven" trials where traditional and new methodology data can be submitted alongside each other to build up experience in the new methods. Industry can in turn play its part in the acceptance of new methodology, by inputting into the setting of performance standards and by actively contributing to "safe haven" trials.
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